Justin

Case Study: Use of CancerTYPE ID in Cancer of Unknown Primary (CUP)

637 0 Acute Lymphoblastic Leukemia

Dr. Greco speaks about the usage of CancerTYPE ID to obtain a single diagnosis in patient with Cancer of Unknown Primary or CUP.

For more information, visit http://www.cancertypeid.com

Play Add to

Managing Costs in Oncology Care

445 0 Acute Lymphoblastic Leukemia

Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can help compared to other options.

For more information, visit: http://www.cancertypeid.com

Play Add to

CancerTYPE ID in the Clinic Dr. Boccia

479 0 Acute Lymphoblastic Leukemia

Dr. Boccia describes cases in which he uses CancerTYPE ID in his clinical practice.

For more information, visit: http://www.cancertypeid.com

Play Add to

Comparison of Molecular Diagnostic Tests and Clinical Validation of CancerTYPE ID

623 0 Acute Lymphoblastic Leukemia

Dr. Boccia compares CancerTYPE ID to other gene expression tests and reviews studies validating its accuracy and clinical utility.

For more information, visit: http://www.cancertypeid.com

Play Add to

The bioT3 Platform

506 0 Acute Lymphoblastic Leukemia

Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy.

For more information, visit: http://www.cancertypeid.com

Play Add to

Unclear Diagnoses in Patients with Metastatic Disease

540 0 Acute Lymphoblastic Leukemia

Dr. Boccia addresses the problem of unclear diagnoses affecting approximately 15% of newly diagnosed patients with metastatic disease each year and the importance of an accurate diagnosis of tumor type in selecting the proper site-specific therapies.

For more information, visit: http://www.cancertypeid.com

Play Add to

Justin

Comparison of Molecular Diagnostic Tests and Clinical Validation of CancerTYPE ID

Date added (newest)

Case Study: Use of CancerTYPE ID in Cancer of Unknown Primary (CUP)

Managing Costs in Oncology Care

CancerTYPE ID in the Clinic Dr. Boccia

Comparison of Molecular Diagnostic Tests and Clinical Validation of CancerTYPE ID

The bioT3 Platform

Unclear Diagnoses in Patients with Metastatic Disease

Case Study: Use of CancerTYPE ID in Cancer of Unknown Primary (CUP)

Dr. Greco speaks about the usage of CancerTYPE ID to obtain a single diagnosis in patient with Cancer of Unknown Primary or CUP.

For more information, visit http://www.cancertypeid.com

Managing Costs in Oncology Care

Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can help compared to other options.

For more information, visit: http://www.cancertypeid.com

CancerTYPE ID in the Clinic Dr. Boccia

Dr. Boccia describes cases in which he uses CancerTYPE ID in his clinical practice.

For more information, visit: http://www.cancertypeid.com

Comparison of Molecular Diagnostic Tests and Clinical Validation of CancerTYPE ID

Dr. Boccia compares CancerTYPE ID to other gene expression tests and reviews studies validating its accuracy and clinical utility.

For more information, visit: http://www.cancertypeid.com

The bioT3 Platform

Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy.

For more information, visit: http://www.cancertypeid.com

Unclear Diagnoses in Patients with Metastatic Disease

Case Study: Use of CancerTYPE ID in Cancer of Unknown Pri...

Justin

Comparison of Molecular Diagnostic Tests and Clinical Validation of CancerTYPE ID

Date added (newest)

Case Study: Use of CancerTYPE ID in Cancer of Unknown Primary (CUP)

Managing Costs in Oncology Care

CancerTYPE ID in the Clinic Dr. Boccia

Comparison of Molecular Diagnostic Tests and Clinical Validation of CancerTYPE ID

The bioT3 Platform

Unclear Diagnoses in Patients with Metastatic Disease

Case Study: Use of CancerTYPE ID in Cancer of Unknown Primary (CUP)

Dr. Greco speaks about the usage of CancerTYPE ID to obtain a single diagnosis in patient with Cancer of Unknown Primary or CUP. For more information, visit http://www.cancertypeid.com

Managing Costs in Oncology Care

Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can help compared to other options. For more information, visit: http://www.cancertypeid.com

CancerTYPE ID in the Clinic Dr. Boccia

Dr. Boccia describes cases in which he uses CancerTYPE ID in his clinical practice. For more information, visit: http://www.cancertypeid.com

Comparison of Molecular Diagnostic Tests and Clinical Validation of CancerTYPE ID

Dr. Boccia compares CancerTYPE ID to other gene expression tests and reviews studies validating its accuracy and clinical utility. For more information, visit: http://www.cancertypeid.com

The bioT3 Platform

Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy. For more information, visit: http://www.cancertypeid.com

Unclear Diagnoses in Patients with Metastatic Disease

Case Study: Use of CancerTYPE ID in Cancer of Unknown Pri...

Dr. Greco speaks about the usage of CancerTYPE ID to obtain a single diagnosis in patient with Cancer of Unknown Primary or CUP.

For more information, visit http://www.cancertypeid.com

Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can help compared to other options.

For more information, visit: http://www.cancertypeid.com

Dr. Boccia describes cases in which he uses CancerTYPE ID in his clinical practice.

For more information, visit: http://www.cancertypeid.com

Dr. Boccia compares CancerTYPE ID to other gene expression tests and reviews studies validating its accuracy and clinical utility.

For more information, visit: http://www.cancertypeid.com

Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy.

For more information, visit: http://www.cancertypeid.com